{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:35:36Z","timestamp":1761766536403,"version":"3.40.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.leukres.2019.05.004","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T10:43:06Z","timestamp":1557744186000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-4742","authenticated-orcid":false,"given":"Omer","family":"Jamy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rehan","family":"Sarmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.leukres.2019.05.004_bib0005","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.leukres.2019.05.004_bib0010","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2019.05.004_bib0015","article-title":"Survival of chronic myeloid leukemia patients in comparison to general population in the tyrosine kinase inhibitors era: a US population based study","volume":"130","author":"Sarmad","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2019.05.004_bib0020","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2019.05.004_bib0025","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"issue":"35","key":"10.1016\/j.leukres.2019.05.004_bib0030","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2019.05.004_bib0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2019.05.004_bib0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/sj.leu.2404025","article-title":"Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib","volume":"20","author":"Pilot","year":"2006","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2019.05.004_bib0045","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/aje\/kwq262","article-title":"Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study","volume":"172","author":"Rebora","year":"2010","journal-title":"Am. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.leukres.2019.05.004_bib0050","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4149\/neo_2011_03_256","article-title":"Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia","volume":"58","author":"Voglova","year":"2011","journal-title":"Neoplasma"},{"issue":"9","key":"10.1016\/j.leukres.2019.05.004_bib0055","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3324\/haematol.2017.169532","article-title":"Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia","volume":"102","author":"Gugliotta","year":"2017","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.leukres.2019.05.004_bib0060","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2019.05.004_bib0065","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3109\/10428194.2012.668684","article-title":"Chronic myeloid leukemia and risk of second malignancy in two eras of treatment","volume":"53","author":"Stein","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.leukres.2019.05.004_bib0070","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.2001.19.2.464","article-title":"Solid cancers after bone marrow transplantation","volume":"19","author":"Bhatia","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2019.05.004_bib0075","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/jnci\/djr533","article-title":"Second malignant neoplasms and cardiovascular disease following radiotherapy","volume":"104","author":"Travis","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.leukres.2019.05.004_bib0080","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2019.05.004_bib0085","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2019.05.004_bib0090","first-page":"195","article-title":"Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution, hematology (Amsterdam","volume":"13","author":"Radaelli","year":"2008","journal-title":"Netherlands"},{"issue":"12","key":"10.1016\/j.leukres.2019.05.004_bib0095","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","article-title":"Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia","volume":"53","author":"Steegmann","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2019.05.004_bib0100","unstructured":"Glivec-Summary of product characteristics."},{"issue":"4","key":"10.1016\/j.leukres.2019.05.004_bib0105","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00280-010-1394-x","article-title":"Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells","volume":"67","author":"Rappa","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"8","key":"10.1016\/j.leukres.2019.05.004_bib0110","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/sj.leu.2403401","article-title":"Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro","volume":"18","author":"Cwynarski","year":"2004","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2019.05.004_bib0115","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1634\/stemcells.2005-0069","article-title":"Effects of imatinib on normal hematopoiesis and immune activation","volume":"23","author":"Appel","year":"2005","journal-title":"Stem cells (Dayton, Ohio)"},{"issue":"12","key":"10.1016\/j.leukres.2019.05.004_bib0120","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-015-2494-9","article-title":"Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML","volume":"94","author":"Fabarius","year":"2015","journal-title":"Ann. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2019.05.004_bib0125","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/sj.leu.2403874","article-title":"Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia","volume":"19","author":"Roy","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2019.05.004_bib0130","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.59","article-title":"Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia","volume":"30","author":"Gunnarsson","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2019.05.004_bib0135","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3109\/10428194.2012.666545","article-title":"Secondary malignancy after imatinib therapy: eight cases and review of the literature","volume":"53","author":"Duman","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2019.05.004_bib0140","doi-asserted-by":"crossref","first-page":"e2015003","DOI":"10.4084\/mjhid.2015.003","article-title":"Occurrence of secondary malignancies in chronic myeloid leukemia during therapy with imatinib mesylate-single institution experience","volume":"7","author":"Helbig","year":"2015","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"6","key":"10.1016\/j.leukres.2019.05.004_bib0145","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2016.20","article-title":"Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV","volume":"30","author":"Miranda","year":"2016","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.leukres.2019.05.004_bib0150","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood-2011-06-362889","article-title":"Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies","volume":"118","author":"Verma","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2019.05.004_bib0155","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12288-013-0328-2","article-title":"Second primary malignancies in chronic myeloid leukemia","volume":"30","author":"Shah","year":"2014","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"5","key":"10.1016\/j.leukres.2019.05.004_bib0160","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.13346","article-title":"Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era","volume":"169","author":"Gunnarsson","year":"2015","journal-title":"Br. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T04:19:37Z","timestamp":1559794777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619300918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":32,"alternative-id":["S0145212619300918"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.05.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}